FDA Approves New Influenza Vaccine Production FacilityMay 7th, 2009 - 4:28 pm ICT by admin
The U.S. Food and Drug Administration (FDA) today announced that it has approved a new manufacturing facility used to produce influenza virus vaccines. The facility is approved for seasonal influenza vaccine production and could be used for the production of vaccine against the new 2009 H1N1 influenza strain.
As part of its overall pandemic influenza preparedness efforts, the FDA meets with vaccine manufacturers to guide the efficient establishment of influenza vaccine facilities that comply with agency requirements. The agency promptly reviews applications and manufacturing supplements that could increase both the number of manufacturers and the overall supply of vaccine.
The facility, located in the United States, is owned and operated by sanofi pasteur, which manufactures Fluzone Influenza Virus Vaccine. This new facility will greatly increase sanofi pasteur’s production capability.
“This approval represents an important step towards increasing the availability of influenza vaccines,” said Karen Midthun, M.D., the FDA’s acting director of the Center for Biologics Evaluation and Research.
“Increased manufacturing capacity for influenza vaccine is critical to our preparedness for an influenza pandemic,” said Jesse Goodman, M.D., M.P.H., the FDA’s acting chief scientist and deputy commissioner for scientific and medical programs. “This action also enhances the ability to produce and provide vaccines to protect the public from seasonal influenza, still estimated to cause more than 30,000 deaths per year. Thanks to strategic investments by the federal government and proactive efforts and engagement by the FDA and the vaccine industry, our nation’s preparedness has come a long way over the last five years.”
The FDA has interacted with the company throughout the regulatory process to help ensure compliance with applicable requirements.
The bulk manufacturing facility will be used for the production of Fluzone, sanofi pasteur’s egg-based influenza vaccine.
Sanofi Pasteur is located in Swiftwater, Pa.
Information on the FDA’s response to the new 2009 H1N1 influenza virus may be found on the FDA’s Web site at http://www.fda.gov/h1n1flu/default.htm.
Information on seasonal influenza vaccine may be found on the FDA’s Web site at http://www.fda.gov/cber/flu/flu.htm.
The FDA’s Pandemic Influenza Preparedness Strategic Plan may be found on the FDA’s Web site at http://www.fda.gov/oc/op/pandemic/strategicplanupdate03_08.html.
- FDA, FTC Warn Public of Fraudulent 2009 H1N1 Influenza Products (Swine Flu) - May 02, 2009
- India likely to start swine flu vaccination next week - Mar 10, 2010
- Spurt in swine flu deaths in Kerala, health ministry to send team - Jun 15, 2010
- Landmark agreement improves global preparedness for influenza pandemics - Apr 18, 2011
- '2009 swine flu pandemic won't return to Maharashtra' - Apr 04, 2012
- 2009 H1N1 vaccine shows promise in children - Sep 22, 2009
- Swine flu claims 10 victims in Britain - Dec 13, 2010
- WHO retracts admission that swine flu was exaggerated (Second Lead) - Apr 06, 2010
- Cuba to give flu shots to over 600,000 people - Nov 20, 2011
- Swine flu scare was exaggerated, admits WHO (Lead) - Apr 06, 2010
- Scientists use insect cells technology for producing swine flue vaccine - Jan 05, 2010
- 'No mutation of swine flu virus' - Apr 11, 2012
- US to begin clinical trials of swine flu vaccine - Jul 23, 2009
- Young child among eleven H1N1 flu deaths in Jordan - Jan 23, 2011
- More seizures in children with H1N1 virus than those with seasonal flu - Sep 20, 2010
Tags: applicable requirements, chief scientist, deputy commissioner, food and drug administration, food and drug administration fda, influenza, influenza pandemic, influenza strain, influenza vaccine production, influenza vaccines, influenza virus vaccine, jesse goodman, medical programs, pandemic influenza preparedness, preparedness efforts, proactive efforts, production capability, strategic investments, vaccine manufacturers, virus vaccines